Skip to content
Medical Health Aged Care

Gyder Surgical Announces 510(k) FDA clearance for the GYDER® Hip System, the World’s First Commercially Available Pin-less and Image-less Solution for Accurate Positioning of the Acetabular Cup during Anterior Hip Arthroplasty

Gyder Surgical 2 mins read

MULGRAVE, Australia & PALO ALTO, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Gyder Surgical, a MedTech company specializing in intuitive, orthopaedic navigation solutions, today announced the 510(k) FDA clearance for the GYDER® Hip System, the world’s first commercially available non-invasive (pin-less) and image-less solution for the accurate positioning of the acetabular cup during Anterior Hip Arthroplasty. The FDA’s clearance decision is the second significant regulatory milestone for the GYDER® Hip System, which received Australia’s TGA regulatory approval previously. Surgical cases have already been successfully performed in Australia and India.

Improving acetabular cup placement accuracy is clinically important with significant potential to reduce post-surgery complications, thereby improving patient outcomes and lowering health system cost burden. An estimated 700,000 hip procedures are performed annually in the United States, with growing demand driven by aging demographics and more active lifestyles. Unlike traditional hip navigation approaches, the GYDER® Hip System’s patented technology does not use invasive metallic pins. Developed by Gyder Surgical, the innovation also does not rely on pre-operative or intra-operative imaging for anatomical landmark registration. One-minute calibration and quick registration make the GYDER® Hip Navigation System a fast, easy-to-use computer-assisted navigation solution that seamlessly integrates into existing surgical workflows.

“The FDA 510(k) clearance of the GYDER® Hip System marks a significant milestone in bringing this innovation to surgeons in the world’s largest hip replacement market. The GYDER® Hip System is well suited for use in the fast-growing Ambulatory Surgery Center (outpatient) segment, with its small footprint, low training burden, speed, and efficiency. We believe the best solutions minimize complexity and do not require surgeons to change their practice significantly. And the GYDER® Hip System does exactly that.” Sujit Dike, CEO, Gyder Surgical.

About Gyder Surgical

Gyder Surgical specializes in intuitive, orthopaedic navigation products. We believe every patient should have access to accurate and precise surgery, no matter where they are. The GYDER® Hip Navigation System, our first product, is designed to assist surgeons in accurately placing the acetabular cup during Anterior Hip Replacement Surgery. Gyder Surgical is a member of the 2024 Medtech Innovator Asia Pacific cohort (https://medtechinnovator.asia/).

For media inquiries or further information, please contact [email protected].

Website: www.gydersurgical.com
LinkedIn: https://www.linkedin.com/company/gyder-surgical

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c0f6b709-4bcb-43d8-bf61-cd8e88584449


Primary Logo

More from this category

  • Medical Health Aged Care
  • 17/06/2025
  • 18:41
Ferrer

Ferrer Receives FDA Fast Track Designation for FNP-223 in Progressive Supranuclear Palsy (PSP)

BARCELONA, Spain--BUSINESS WIRE-- Ferrer, a B Corp-certified international pharmaceutical company, has announced that FNP-223, a novel therapy in-licensed from Asceneuron and aimed at slowing the development of progressive supranuclear palsy (PSP), has received Fast Track designation from the US Food & Drug Administration (FDA). FNP-223, a new molecular entity in active development for PSP, is in an ongoing Phase 2 study to evaluate its safety, efficacy, and pharmacokinetics in adult patients with possible or probable PSP-Richardson syndrome (PSP-RS), the most common clinical variant of this neurodegenerative disease1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617437460/en/Ferrer's pharmaceutical production…

  • Contains:
  • Education Training, Medical Health Aged Care
  • 17/06/2025
  • 11:55
SUADA PR

Applications have just opened for the 2025 First Nations Cancer Scholarship Program

MEDIA RELEASE Applications Open for $5.9 Million First Nations Cancer Scholarship Fund Supporting Indigenous leadership in cancer care and research Tuesday, 17 June 2025 Aurora Education Foundation, in partnership with Cancer Australia, is now accepting applications for the 2025 round of the First Nations Cancer Scholarships, a $5.9 million program supporting Aboriginal and Torres Strait Islander leadership in cancer control. Funded by the Australian Government through Cancer Australia, the Scholarship provides up to $120,000 per year up to three years, as well as academic, wellbeing and community support. It is open to Aboriginal and Torres Strait Islander students, health professionals…

  • Medical Health Aged Care
  • 17/06/2025
  • 06:30
RMIT University

New pathway for mRNA drug delivery shows shape of things to come

Scientists have discovered that the internal shape of tiny drug-delivery particles – called lipid nanoparticles – has a big impact on how well our…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.